Anti-inflammatory activity of a short peptide designed for anti-cancer: a beneficial off-target effect of tertomotide
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Tertomotide is a peptide vaccine developed for anti-cancer therapy. Since it has been found to ameliorate inflammatory symptoms in animal studies and clinical test, we investigated anti-inflammation activity of the tertomotide and the mechanism of action in monocyte in order to assess if tertomotide may serve as an anti-inflammatory agent by checking inflammatory cytokines and related signaling pathway following tertomotide treatment. We found that tertomotide reduced the level of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-8 in LPS- or PMA-stimulated monocyte cell line and suppressed NF-κB signaling including the activation of ERK1/2 and P38 MAPK following TNF-α treatment. These results may correlate to the beneficial findings in animal studies, implicating that tertomotide may act as a potential anti-inflammatory agent. This study is an exemplary case for convergence that a computationally designed peptide for immunological purpose exerting unexpected biological activity may elicit novel anti-inflammatory drug.
Abstract
Tertomotide is a peptide vaccine developed for anti-cancer therapy. Since it has been found to ameliorate inflammatory symptoms in animal studies and clinical test, we investigated anti-inflammation activity of the tertomotide and the mechanism of action in monocyte in order to assess if tertomotide may serve as an anti-inflammatory agent by checking inflammatory cytokines and related signaling pathway following tertomotide treatment. We found that tertomotide reduced the level of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-8 in LPS- or PMA-stimulated monocyte cell line and suppressed NF-κB signaling including the activation of ERK1/2 and P38 MAPK following TNF-α treatment. These results may correlate to the beneficial findings in animal studies, implicating that tertomotide may act as a potential anti-inflammatory agent. This study is an exemplary case for convergence that a computationally designed peptide for immunological purpose exerting unexpected biological activity may elicit novel anti-inflammatory drug.
참고문헌 (16)
- N. Relitti, "Telomerase-based cancer therapeutics: A review on their clinical trials", Current Topics in Medicinal Chemistry, 20(6), pp.433~457
- Y. H. Park, "GV1001 inhibits cell viability and induces apoptosis in castrationresistant prostate cancer cells through the AKT", NF-kappaB, Journal of Cancer, pp.2019, 10(25)[DOI]
- V. E. Shaw, "Current status of GV1001and other telomerase vaccination strategies in the treatment of cancer", Expert Review of Vaccines, 9(9), pp.1007~1016 (2010)
- 최지예, "The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production", Immune Network, 15(6), pp.291~303 (2015), 대한면역학회[DOI]
- Y. J. Ko, "The anti-inflammatory effect of human telomerase-derived peptide on P. gingivalis lipopolysaccharide-induced inflammatory cytokine production and its mechanism in human dental pulp cells", Mediators of Inflammation, 2015(385127), pp.1~8 (2015)
- T. Y. Koo, "Protective effect of peptide GV1001 against renal ischemiareperfusion injury in mice", Transplant Proceedings, 46(4), pp.1117~1122 (2014)
- E. K. Lee, "A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model", Translational Research, 216, pp.30~42 (2020)
- Yu-Min Choi, "A Telomerase-Derived Peptide Exerts an Anti-Hepatitis B Virus Effect via Mitochondrial DNA Stress-Dependent Type I Interferon Production", Frontiers in Immunology, 11 (2020), Frontiers Media SA[DOI]
- J. Auwerx, "The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation", Experientia, 47(1), pp.22~31 (1991)
- Y. Zhang, "Therapeutic approaches in mitochondrial dysfunction, inflammation, and autophagy in uremic cachexia: role of aerobic exercise", Mediators in Inflammations, 2019(2879014), pp.1~11 (2019)
- C. Madeddu, "Multitargeted treatment of cancer cachexia", Critical Reviews in Oncogenesis, 17(3), pp.305~314 (2012)
- C. Staff, "Telomerase (GV1001)vaccination together with gemcitabine in advanced pancreatic cancer patients", International Journal of Oncology, 45(3), pp.1293~1303 (2014)
- W. Chanput, "THP-1 cell line: an in vitro cell model for immune modulation approach", International Immuno pharmacology, 23(1), pp.37~45 (2014)
- N. E. Annels, "The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer", Cancer Immunololgy and Immunotherapy, 63(2), pp.175~183 (2014)
- C. C. Hsu, "Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NF-κB and MAPK activation", Biochemical Pharmacology, 85(3), pp.385~395 (2013)
- K. L. Zapadka, "Factors affecting the physical stability(aggregation)of peptide therapeutics", Interface focus, 7(6), pp.20170030~ (2017)